EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis

Juan Peng iD, Huiling Xu, Qiao Liu iD

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0312133 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Juan Peng und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Cost-Benefit Analysis, ErbB Receptors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

This study aims to compare the cost-effectiveness of sintilimab in combination with chemotherapy, with or without bevacizumab biosimilar IBI305, versus chemotherapy alone for patients with epidermal growth factor receptor (EGFR)-mutated non-small-cell lung cancer (NSCLC) who have progressed on tyrosine-kinase inhibitor (TKI) treatment from the perspective of the Chinese healthcare system.

Methods

10-year Markov model was developed using a 21-day cycle length. Transition probabilities were derived from the ORIENT-31 trial, while cost and health state utilities were obtained from publicly databases, local hospitals, and published literature. Incremental cost-effectiveness ratios (ICERs) were calculated as the primary model output and compared to a willingness-to-pay (WTP) threshold range of $15,289.34 to $38,223.34 per quality-adjusted life-years (QALY). Sensitivity analyses were performed to assess the robustness of the model.

Results

In the base-case analysis, sintilimab plus IBI305 and chemotherapy had an ICER of $53,266.32/QALYs, exceeding the upper WTP threshold. Sintilimab plus chemotherapy had an ICER of $15,329.11/QALY, slightly above the lower WTP threshold. Subgroup analysis yielded consistent results. Deterministic sensitivity analyses found no ICER for sintilimab plus chemotherapy beyond the upper WTP threshold. Most model input changes did not decrease the ICER of sintilimab plus IBI305 and chemotherapy below the upper WTP threshold. Probabilistic sensitivity analyses further demonstrated the cost-effectiveness superiority of sintilimab plus chemotherapy over sintilimab plus IBI305 and chemotherapy.

Conclusion

This study supports the cost-effectiveness of using sintilimab in combination with chemotherapy. Nevertheless, the cost-effectiveness of combining sintilimab with IBI305 and chemotherapy in this particular patient group may be lacking.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsCost-Benefit AnalysisErbB ReceptorsAntineoplastic Combined Chemotherapy ProtocolsAntibodies, Monoclonal, HumanizedBevacizumabBiosimilar PharmaceuticalsHumansChinaQuality-Adjusted Life YearsMutationProtein Kinase InhibitorsMaleMarkov ChainsFemaleMiddle AgedCost-Effectiveness Analysis

Substanzen

ErbB ReceptorsAntibodies, Monoclonal, HumanizedEGFR protein, humanBevacizumabsintilimabBiosimilar PharmaceuticalsProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Pharmacy, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
  • Department of Pharmacy, The Second Xiangya Hospital of Central South University, Changsha, China.

ORCID-Profile: Juan Peng, Qiao Liu

Zitieren

APA

Peng, J., Xu, H., & Liu, Q. (2024). Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis. PLOS ONE. https://doi.org/10.1371/journal.pone.0312133

Vancouver

Peng J, Xu H, Liu Q. Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis. PLOS ONE. 2024. doi:10.1371/journal.pone.0312133

BibTeX
@article{Peng2024,
  author = {Peng, Juan and Xu, Huiling and Liu, Qiao},
  title = {Sintilimab plus chemotherapy with or without bevacizumab biosimilar IBI305 in EGFR-mutated non-squamous NSCLC patients who progressed on EGFR TKI therapy: A China-based cost-effectiveness analysis},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0312133}
}
Kostenlos starten →